Open AccessRegulation of RAS in human platelets
Author(s) -
Tulasne David,
Bori Teresa,
Watson Steve P.
Publication year - 2002
Publication title -
european journal of biochemistry
Language(s) - English
Resource type - Journals
eISSN - 1432-1033
pISSN - 0014-2956
DOI - 10.1046/j.1432-1033.2002.02798.x
Subject(s) - agonist , thrombin , platelet activation , kinase , mapk/erk pathway , tyrosine kinase , chemistry , proto oncogene tyrosine protein kinase src , microbiology and biotechnology , receptor , grb2 , platelet , biology , biochemistry , immunology
In this study, we show that the G protein‐coupled receptor agonist thrombin, the glycoprotein VI agonist convulxin, and the cytokine receptor Mpl agonist thrombopoietin (TPO) are able to induce activation of RAS in human platelets. Recruitment of GRB2 by tyrosine‐phosphorylated proteins in response to TPO and convulxin but not by thrombin occurred with a similar time‐course to RAS activation, consistent with a causal relationship. On the other hand, activation of ERK2 by thrombin and convulxin is delayed and also inhibited by the protein kinase C inhibitor Ro‐31 8220, whereas RAS activation is unaffected. Further evidence for differential regulation of RAS and ERK is provided by the observations that TPO, which activates RAS but not protein kinase C, does not activate ERK, and that the inhibitor of SRC kinases PP1 inhibits activation of RAS but not ERK2 in response to thrombin. Our results demonstrate that activation of RAS is not necessarily coupled to ERK in human platelets.